Detalhe da pesquisa
1.
An exploratory analysis of the cost-effectiveness of insulin glargine 300 units/mL versus insulin glargine 100 units/mL over a lifetime horizon using the BRAVO diabetes model.
Diabet Med
; 41(5): e15303, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38470100
2.
Cost-effectiveness analysis of once-daily insulin glargine 300 U/mL versus insulin degludec 100 U/mL using the BRAVO diabetes model.
Diabet Med
; 40(9): e15112, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37035994
3.
Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study.
Diabetes Obes Metab
; 24(8): 1617-1622, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35491520
4.
Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial.
Diabetes Obes Metab
; 24(12): 2364-2372, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36053820
5.
How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting?
Diabetes Obes Metab
; 23(3): 838-843, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33236461
6.
Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study.
Diabetes Obes Metab
; 21(9): 2123-2132, 2019 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31144445
7.
Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study.
Endocrinol Diabetes Metab
; 5(1): e00306, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34807513
8.
Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study.
Adv Ther
; 37(9): 3863-3877, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32681460
9.
Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real-world setting.
Endocrinol Diabetes Metab
; 2(3): e00073, 2019 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-31294087